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ABSTRACT 
Objective: The objective of present work is to improve physicochemical and pharmacokinetic profile of poorly water soluble HIV protease 
inhibitor, ritonavir (RT) by preparing its amino acid conjugates.  
Methods: Ester conjugates of ritonavir with various amino acids were synthesized by a simple esterification process using dicyclohexyl 
carbodiimide (DCC) as a coupling agent. The synthesized compounds were characterized by thin layer chromatography (TLC), fourier 
transform infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR) and mass spectroscopy. All conjugates were evaluated by 
saturation solubility and hydrolytic stability studies. Cytotoxicity and permeability studies were conducted using Caco-2 cell line. 
Results: All amino acid conjugates showed a significantly higher aqueous solubility compared to the pure RT. With respect to hydrolysis, alkaline 
hydrolysis of conjugates was rapid relative to acidic hydrolysis. No cytotoxicity was shown by conjugates for concentration as high as 100µg/ml, 
which indicates promising therapeutic potential. Permeability of RT across Caco-2 cell monolayers was improved by amino acid conjugation.  
Conclusion: In vitro studies demonstrated that amino acid conjugation of RT may be an effective strategy to improve its aqueous solubility as well 
as permeability and can be used to improve oral absorption and thereby oral bioavailability of protease inhibitors. 
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INTRODUCTION 
Solubility behaviour of a drug is one of the key determinants 
of its oral bioavailability. In the pharmaceutical analysis and 
formulation development fields, it is most often required to 
increase the aqueous solubility of poorly water soluble 
drugs1. Currently, 60% of of all newly developed drugs are 
poorly water soluble or lipophilic in nature2,3. When dosed 
orally, insoluble drugs are not efficiently absorbed from the 
solid state and require specialized formulations to enhance 
their solubility in the gastrointestinal tract. Several 
techniques used to overcome challenges of poor aqueous 
solubility, dissolution rates and insufficient bioavailability 
are reduction of particle-size which includes microsizing and 
nanosizing, salt formation, conjugate or prodrug formation, 
complexation ,solid-dispersions, use of surfactants, 
polymorphism and micellization4-14. The conjuation of a drug 
to different carriers which is also called as a prodrug 
approach is a promising molecular modification by which 
drug pharmacokinetics, pharmacodynamics and toxicology 
can be modulated. Undesirable properties, including poor 
aqueous solubility, chemical instability, insufficient oral or 
local absorption, fast pre-systemic metabolism, low half-life, 
toxicity and local irritation are commonly resolved using the 
conjugation or prodrug approach. In addition, problems 
related to drug formulation and delivery can also be 
overcome by using this strategy15. There are around 10% 
marketed medicines that can be categorized as prodrugs16-
18. 
Transporter targeted conjugate preparation or prodrug 
derivatization is one of the strategies which involve 
utilization of influx transporters which facilitate transport of 
polar nutrients such as amino acids and peptides19,20. This 
strategy has been successfully used in an attempt to increase 
solubility and absorption of poorly absorbed drugs such as 
lopinavir20, saquinavir21, acyclovir22, ganciclovir23-25 and 
zanamivir26. Conjugates can be designed by coupling amino 
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acids/peptides to compounds in a way to resemble the 
intestinal nutrients structurally and get absorbed by specific 
carrier proteins. Amino acids are normal dietary constituent 
and they are nontoxic in moderate doses as compared to 
other promoieties or carriers. The amino acid prodrugs 
improve oral delivery of drugs which have poor permeability 
and solubility.  
Ritonavir (RT) is a widely used, HIV-1 specific protease 
inhibitor which belongs to Class IV in the Biopharmaceutics 
Classification System. It is practically insoluble in water and 
exhibits slow intrinsic dissolution rate. Though ritonavir has 
favorable lipophilicity, in vitro permeability studies have 
shown that it is a substrate of P‐glycoprotein. Thus, the oral 
absorption of ritonavir could be limited by both dissolution 
and permeability27,28. In the present study, amino acid ester 
conjugates of ritonavir were synthesized with a simple 
esterification process. These conjugates were designed to 
examine the effect of amino acids on solubility and 
permeability of RT. These conjugates were characterized by 
their melting points, NMR, mass, FTIR spectroscopy and 
elemental analysis. Solubility in distilled water was 
determined followed by cytotoxicity determinations. 
Transport studies were conducted in Caco-2 cells to 
compare permeability of conjugates with RT. 
MATERIALS AND METHODS  
Materials: 
Ritonavir was obtained from Lupin Pharma Ltd (Pune, 
India). Boc amino acids, dimethylaminopyridine and N, N’-
dicyclohexyl carbodimide, as well as all other reagents and 
solvents were commercially procured from Loba Chemicals 
Pvt. Ltd. (Mumbai, India). The purity of the synthesized 
compounds were confirmed by thin layer chromatography 
using precoated TLC plates (Merck, 20×20, 60F 254). 
Melting points were recorded in open capillary tubes and 
are uncorrected. FTIR spectra were recorded in Bruker FT-
IR spectrometer (Model – Alpha).1H NMR spectra were 
recorded using Bruker AVANCE III 500 MHz (AV 500) multi 
nuclei solution NMR Spectrometer using CDCl3 as the solvent 
and TOPSPIN 3.2 software. Electron-spray ionization mass 
spectra (ESI–MS) were recorded on Bruker Impact II UHR-
TOF Mass spectrometer system by electron ionization (EI) 
technique. This method used in positive mode gives either 
(M+H) + and/or (M+Na) + signal.  
Methods: 
Synthesis of ester conjugates of ritonavir 
Step I: Reaction of Boc protected amino acids with 
lopinavir: 
To the well stirred and cooled solution of ritonavir (0.57 g, 
0.8 mmol) in dichloromethane dimethylaminopyridine (0.19 
g, 1.6 mmol) was added to activate the secondary hydroxyl 
group of RT and continuously stirred for 10min at 0ºC under 
anhydrous conditions. Then Boc-amino acid (valine, glycine, 
alanine and serine 1.6 mmol) and N, N-Dicyclohexyl 
carbodimide (0.49 g, 2.4 mmol) were added to the reaction 
mixture. The mixture was stirred at 0ºC for one hour and at 
room temperature for the next 90 hours. To ensure complete 
conversion of reactants to product the reaction mixture was 
analysed by TLC. The mixture was filtered and dried over 
Na2SO4. The solvent was evaporated under reduced pressure 
at room temperature to obtain dried product. 
Step II: Deprotection of the N-Boc Group  
Boc-amino acid-RT was treated with 1:1 trifluroacetic acid/ 
dicholoromethane (TFA/CH2Cl2) mixture at 0°C for about 2 
h. The solvent was evaporated under vacuum. The crude oily 
product, amino acid-RT, was purified by recrystallization 
from cold diethyl ether.  
Characterization of conjugates 
Conjugates were characterized by FT-IR, 1H NMR and Mass 
spectroscopy. The purity was determined using TLC and 
physicochemical parameters were determined. 
Solubility Study: 
Saturated solutions of drug and conjugates were prepared in 
distilled water in 25 mL conical flasks and kept at room 
temperature (RT) for 24 h in a mechanical shaker. Solutions 
were centrifuged for 10 min to separate undissolved 
conjugates. The supernatant was separated, filtered and 
analyzed by UV spectrophotometer at 239nm after 
appropriate dilutions29. The samples were studied in 
triplicate and the results were presented as the mean values.  
In Vitro Hydrolysis Study:   
Chemical hydrolysis study of prodrugs was carried out in an 
aqueous buffer solution at pH 1.2 and pH 7.4 at 37 °C using 
hydrochloric acid and phosphate buffer respectively and 
degradation rate constant and half-life (t1/2) of conjugates 
were determined. Solutions of 10 mg of conjugate prepared 
in 90 mL of Hydrochloric acid buffer (pH 1.2) or phosphate 
buffer (pH 7.4) were kept in screw-capped tubes and placed 
in shaking water bath (60 rpm) at 37 °C. At predetermined 
time points, aliquots were withdrawn from tubes and 
analyzed by UV spectrophotometer for the amount of drug 
released after the hydrolysis of conjugates. Pseudo first 
order rate constants for the degradation (Kobs) and half-life 
(t1/2) were calculated30,31. 
Cytotoxicity Studies  
MTT [(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide)] assay was carried out to determine cytotoxicity of 
conjugates in Caco-2 cells. The amount of MTT cleaved is 
directly proportional to the number of viable cells present, 
which is quantified by colorimetric methods. Briefly the 
compounds were dissolved in DMSO and serially diluted 
with complete medium to get the concentrations a range of 
test concentration. DMSO concentration was kept < 0.1% in 
all the samples. Caco2 cells maintained in appropriate 
conditions were seeded in 96 well plates and treated with 
different concentrations of the test samples (5–200 μg/ml) 
and incubated at 37 °C, 5% CO2 for 4 hours. MTT reagent 
was added to the wells and incubated for 2 hours at 37 °C; 
the dark blue formazan product formed by the cells was 
dissolved in DMSO. Cell viability was determined by 
measuring absorbance at 550nm. 
The quantity of formazan product as measured by absorbance is 
directly proportional to the number of viable cells in test 
samples.  
Permeability/Transport studies:    
Permeability studies were conducted across Caco-2 cell 
monolayers grown on 12 well Transwell® inserts. Cell 
monolayers were washed thoroughly with DPBS (pH7.4) for 
15 min at 37 °C, three times. Transport studies were 
conducted across caco-2 cells for a period of 3 h at 37 °C. For 
determining apical-to-basolateral permeability (A-B), 0.5 mL 
RT or conjugate solution was added to the apical chamber 
and 1.5ml of transport buffer was added to the basolateral 
side of the Transwell® plates. Aliquots were withdrawn at 
predetermined time intervals (30, 60, 120 and 180 min) 
from the receiver chamber and replaced with fresh DPBS pH 
7.4 to maintain sink conditions. The concentrations of the 
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test compounds in the transport medium were immediately 
analyzed by UV spectrophotometry at a wavelength of 
239nm [32]. 
The apical-to-basolateral permeability coefficient (Papp in 
cm/second) was calculated according to following equation: 
 
where Q is the cumulative amount of drug/conjugate 
appearing in the basolateral compartment, A is the surface 
area of insert(cm2), Co – the initial concentration of 
drug/conjugate in apical compartment (mg/mL)33.  
Statistical Analysis  
Solubility and cytotoxicity study results were expressed as 
mean ± S.D. Student’s t-test was applied to determine the 
statistical significance among groups. P values ≤0.05 were 
considered statistically significant.  
RESULTS AND DISCUSSION  
Chemistry  
The ritonavir ester conjugates were synthesized by 
dicyclohexyl carbodiimide (DCC) coupling method using 
dimethylaminopyridine as a catalyst. Amino acids, glycine, 
alanine, valine and serine were identified as carriers for the 
synthesis of conjugates. All conjugates were evaluated by 
solubility, physicochemical characterization and hydrolytic 
studies. Purity of synthesized conjugates was determined by 
thin layer chromatography (TLC). The products were 
obtained in good yields (82-90%). The structures of 
compounds were confirmed by FTIR, 1H NMR and Mass 
spectroscopic data. The IR spectra of these compounds show 
characteristic C=O stretching bands around 1730–1740 cm-1 
and C-O stretching bands around 1223–1251 cm-1 for the 
ester functional group. The 1H NMR spectra of synthesized 
conjugates show the chemical shift values and signals 
characteristic to the functionalities of the amino acids 
leading to the confirmation of the structures assigned to the 
target conjugates. The mass spectroscopic analysis gives the 
(M+H) + peak confirming molecular weight of the targeted 
compounds. 
Spectral data: 
(2S,3S,5S)-5-(2-(3-((2-isopropylthiazol-4-yl)methyl)-3-
methylureido)-3 methylbutanamido)-1,6-diphenyl-2-
(((thiazol-5ylmethoxy)carbonyl)amino)hexan-3-yl 
glycinate (RTG) 
%Yield: 90.2; UV (λmax): (MeOH) 239 nm, IR (cm-1): 
3323.51 (N-H str. amine), 2969.66(C-H str. aromatic), 
1735.25 (C = O str. ester), 1223.88 (C-O str. ester), 1642.26, 
1520.59 (C = C str. aromatic) 1H NMR (500 MHz, CDCl3) δ 
0.84-0.88 (d,6H), 1.02-1.07(d,6H), 1.25-1.29 (d,6H), 1.62-
1.64 (d,2H), 1.93-1.94 (d,1H), 2.10 (d,1H), 2.93-2.94 (d,2H), 
3.21 (s,2H), 3.47 (d,1H),4.04-4.41 (m,3H), 5.19 (s,2H), 6.71-
6.73 (d,1H), 7.13-7.27 (m,10H), 7.85-7.86 (d,1H), 8.80 (s,1H) 
ESI-MS: 778.7 (M+H)+  
(2S,5S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-(3-
methyl-2-(2-oxotetrahydropyrimidin-1(2H)-
yl)butanamido)-1,6-diphenylhexan-3-yl alaninate (RTA) 
%Yield: 84.4; UV (λmax): (MeOH) 238 nm, IR (cm-1): 
3342.75 (N-H str. amine), 2966.47 (C-H str. aromatic), 
1738.16 (C = O str. ester), 1251.60 (C-O str. ester), 1640.65, 
1516.39 (C = C str. aromatic) 1H NMR (500 MHz, CDCl3) δ 
0.85-0.91 (d, 6H), 1.11-1.18(d, 6H), 1.68-1.72 (d, 2H), 1.91-
1.93(d,2H), 2.69 (s,3H), 2.92-2.93 (d,2H), 3.21 (s,2H), 3.44-
3.45(s,1H,OH), 3.62-3.66 (d,2H),  5.27-5.29(d,1H), 6.72-6.74 
(d,1H),7.20-7.26 (m,10H),7.78-7.79 (d,1H),  8.70-8.71 (d,1H) 
ESI-MS: 792.9 (M+H)+  
(2S,5S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-(3-
methyl-2-(2-oxotetrahydropyrimidin-1(2H)-
yl)butanamido)-1,6-diphenylhexan-3-yl valinate (RTV) 
%Yield: 82.6; UV (λmax): (MeOH) 238 nm, IR (cm-1): 
3338.44 (N-H str. amine), 2965.64 (C-H str. aromatic), 
1740.44 (C = O str. ester), 1230.71 (C-O str. ester), 
1520.99(C = C str. aromatic) 1H NMR (500 MHz, CDCl3) δ 
1.14-1.16 (d, 6H), 1.25-1.34 (d, 6H), 1.72-1.74(d, 2H), 1.86-
1.92 (m, 6H), 2.11(s, 6H), 2.27-2.31(s,2H), 3.75(s, 2H), 4.05-
4.26 (m,2H), 4.39 (s,1H), 6.71-6.82 (m, 3H), 6.95-7.27(m, 
10H) ESI-MS: 821.38 (M+H)+  
(2S,5S)-2-(2-(2,6-dimethylphenoxy)acetamido)-5-(3-
methyl-2-(2-oxotetrahydropyrimidin-1(2H)-
yl)butanamido)-1,6-diphenylhexan-3-yl serinate (RTS) 
%Yield: 85.3; UV (λmax): (MeOH) 239 nm, IR (cm-1): 
3413.33 (N-H str. amine), 3288.55 (O-H str), 2966.47(C-H 
str. aromatic), 1730.58 (C = O str. ester), 1251.60 (C-O str. 
ester), 1640.65, 1516.39 (C = C str. aromatic) 1H NMR (500 
MHz, CDCl3) δ 0.81-0.83 (d,6H), 1.72-1.75(d, 2H), 1.90-1.92 
(d, 2H), 2.12-2.19(m,1H), 2.29 (s,2H), 3.03-3.10 (m,3H), 
3.18-3.20 (m,1H), 3.50 – 3.43 (m, 2H), 3.70(s,2H), 6.71-6.72 
(d,1H), 6.93-7.00 (m,2H), 7.13-7.17(m,1H), 7.20-
7.30(m,10H) ESI-MS: 808.9(M+H)+  
Solubility study: 
Solubility studies were carried out in distilled water. All 
amino acid conjugates of ritonavir exhibited higher 
solubility compared to parent drug (Table 1). Serine 
conjugate of ritonavir showed maximum water solubility. 
Currently, RT is administered to HIV-1 infected patients in 
the form of approximately 43% v/v alcoholic solution 
(NORVIR) as it is practically insoluble in water. Such high 
alcohol concentrations may not be suitable for pediatric 
patients. In contrast, amino acid conjugates might offer 
potential advantages due to their higher solubility relative to 
RT.
  
Table 1: Physicochemical and kinetic data for the hydrolysis of ritonavir conjugates at different pH at 370C 
Compound 
Rf  
Value* 
Solubility (mg/ml) 
pH 1.2 pH 7.4 
Kobs (h-1) t1/2 (h) Kobs (h-1) t1/2 (h) 
RT 4.12 0.025± 0.001 
  
  
RTG 2.69 0.37 ± 0.05 0.046 14.86 0.096 7.19 
RTA 3.15 0.35 ± 0.03 0.039 17.35 0.075 9.14 
RTV 3.32 0.58 ± 0.04 0.032 21.40 0.072 9.51 
RTS 2.19 0.75 ± 0.06 0.050 13.84 0.107 6.45 
*TLC (Chloroform:Ethyl acetate:Acetone (50:20:30). 
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Chemical Stability:   
Amino acid ester conjugates of ritonavir degraded rapidly at 
higher pH relative to lower pH. All the conjugates displayed 
higher stability under acidic conditions while undergo base 
catalyzed hydrolysis. The hydrolytic reconversion rate to 
parent drug increased with decreasing side chain length as 
well as increasing pH. The chemical degradation of ester 
conjugates of ritonavir followed first order kinetics. The rate 
constants (Kobs) and the corresponding half-lives (t1/2) for 
the respective conjugates were calculated from the linear 
regression equations correlating the log concentration of the 
residual conjugates vs. time. Degradation half-lives of 
conjugates at pH 1.2 ranged between 13.8-21.4h while at pH 
7.4 ranged between 6.4-9.5h. The results are summarized in 
Table 1.  
Cytotoxicity Studies  
Cytotoxicity of RT and conjugates was determined in Caco-2 
cells with MTT assay. Results obtained from this study are 
demonstrated in fig. 1. Blank medium (without any drug) 
was used as control. Doxorubicin (500µg/ml) was used as 
positive control. DMSO concentration was kept < 0.1% in all 
the samples. Conjugates did not exhibit any cell cytotoxicity 
upto a concentration of 100 µg/ml while RT generated 
cytotoxic effects at 100 µg/ml. Conjugates were found to be 
significantly cytotoxic at 200 µg/ml. Based on these results 
permeability studies were carried out at concentrations ≤50 
µg/ml to prevent cytotoxic effects of conjugates.  
 
 
* Statistically significant.   P < 0.05 with respect to control.  
Figure 1: Cytotoxicity result of ritonavir conjugates in Caco-2 cells. 
 
Permeability study:  
The permeability of RT and its ester conjugates was 
estimated across the apical cell layer of human colon 
adenocarcinoma cell line (Caco-2). Caco-2 is one of most 
frequently used cell lines for the determination of drug 
permeability across intestinal membranes.  Caco-2 cells have 
been reported to express P-gp and peptide transporters. 
Apparent permeability generated by ritonavir across Caco-
2cells in A-B direction was 3.7 × 10−6 whereas for glycine, 
alanine, valine and serine conjugates were 5.2 × 10−6, 5.9 × 
10−6, 7.4 × 10−6 and 5.5 × 10−6 cm/s respectively.  Apical to 
basolateral permeability of RTG, RTA, RTV and RTS was 
about 1.4, 1.6, 2.0 and 1.5-fold higher relative to RT (fig.2). 
All the amino acid conjugates tested showed higher 
permeability compared to RT which may be due to their 
reduced recognition by efflux carriers (P-gp) relative to RT.  
Thus it is concluded that synthesized amino acid ester 
conjugates are good substrates for the amino acid 
transporters expressed on the intestinal barrier and may be 
translocated efficiently resulting in higher oral 
bioavailability. 
 
*Statistically significant.  P < 0.05 with respect to control (RT). 
Figure 2: Permeability of conjugates as compared to 
drug in Caco-2 cells. 
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CONCLUSION 
The present study utilizes amino acids to prepare ester 
conjugates of ritonavir in order to improve its 
physicochemical and pharmacokinetic profile and 
consequently therapeutic effectiveness. Direct conjugation of 
amino acids not only improved solubility but also led to 
enhancement in absorptive flux of ritonavir. This study 
confirms that the amino acid conjugation approach has the 
potential to improve oral absorption and thereby oral 
bioavailability of protease inhibitors.  
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